If you have been reading about preclinical research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-18. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
=== Nonclassical === Nonclassical describes those carbonyl complexes where νCO is higher than that for free carbon monoxide. In nonclassical CO complexes, the C-O distance is shorter than free CO (113.7 pm). The structure of [Fe(CO)6]2+, with dC-O = 112.9 pm, illustrates this effect. These complexes are usually cationic, sometimes dicationic.
=== Pharmacokinetics === A study comprehensively reviewed the metabolism of 3-HO-PCE by using human liver microsomes and samples, both biological and non-biological, from a volunteer. The first major metabolic pathway involves N-dealkylation, yielding the primary amine metabolite 3-HO-PCA. The second pathway causes the molecule to undergo oxidation, creating phenol-3-HO-PCE and hydroxy-3-HO-PCE. These compounds then undergo dehydration, creating dehydro-3-HO-PCE (which is also created directly from the parent compound via dehydrogenation). The third pathway causes the parent compound to undergo oxidative deamination, creating 1-(3'-hydroxyphenyl) cyclohexanol. This compound can either undergo oxidation and dehydrogenation to form dihydroxy-[1,1'-bi(cyclohexan)]-1-en-3-one, or a pathway involving dehydration and allylic oxidation to eventually form 3'4'-dihydro-[1,1'-biphenyl]-3-ol. The fourth pathway is phase II conjugation, where the parent compound undergoes O-glucuronidation to form 3-OGlu-PCE.
manufacturers of processed food, aware of the possible contribution of their products to the obesity epidemic, met together and discussed the problem as early as April 8, 1999; however, a proactive strategy was considered and rejected. As a general rule, optimizing the amount of salt, sugar and fat in a product will improve its palatability, and profitability. Reducing salt, sugar and fat, for the purpose of public health, had the potential to decrease palatability and profitability. Media influence may play an important role in prevention of obesity as it has the ability to boost many of the main prevention/intervention methods used nowadays including lifestyle modification. The media is also highly influential on children and teenagers as it promotes healthy body image and sets societal goals for lifestyle improvement. Examples of media influence are support for the "Let's Move!" campaign and the MyPlate program initiated by Michelle Obama, and the NFL's Play60 campaign. These campaigns promote physical activity in an effort to reduce obesity especially for children. In 2011, the Obama administration introduced a $400 million Healthy Food Financing Initiative, the goal of the program is to "create jobs and economic development, and establish market opportunities for farmers and ranchers," as described by the secretary of agriculture, Tom Vilsack. Population-based approaches have been recommended and pursued in the U.S. Obesity is complex because it affects multiple environments, involves multiple industries and sectors, and affects both energy intake and expenditure.
Sources: en.wikipedia.org
== Awards == Archer Martin shared the 1952 Nobel Prize in Chemistry for the invention of partition chromatography with Richard Synge. Archer Martin's 1954 paper with Anthony T. James, "Gas-Liquid Chromatography: A Technique for the Analysis and Identification of Volatile Materials" reported the discovery of gas-liquid chromatography. This was performed at the National Institute for Medical Research in Mill Hill, London, which became the Francis Crick Institute in 2016. It was honoured by a Citation for Chemical Breakthrough Award from the Division of History of Chemistry of the American Chemical Society presented in 2016 to the Francis Crick Institute. Martin was elected a Fellow of the Royal Society in 1950, and made a CBE in 1960.
The conservation and restoration of human remains involves the long-term preservation and care of human remains in various forms which exist within museum collections. This category can include bones and soft tissues as well as ashes, hair, and teeth. Given the organic nature of the human body, special steps must be taken to halt the deterioration process and maintain the integrity of the remains in their existing state. These types of museum artifacts have great merit as tools for education and scientific research, yet also have unique challenges from a cultural and ethical standpoint. Conservation of human remains within museum collections is most often undertaken by a conservator-restorer or archaeologist. Other specialists related to this area of conservation include osteologists and taxidermists.
=== Diabetes Mellitus === Increased levels of proinsulin in the circulatory system relative to mature insulin concentrations can indicate impending insulin resistance and the development of type 2 diabetes. Additional problems with proinsulin that can lead to diabetes include mutations in the number of cysteines present, which could affect correct folding. If the mutation causes only a mild change it could simply stress the endoplasmic reticulum’s ability to properly fold the protein. This stress, after a while, would lead to a decrease in the number of β-cells producing mature insulin, and would then lead to diabetes mellitus.
=== Other effects === Progesterone also has a role in skin elasticity and bone strength, in respiration, in nerve tissue and in female sexuality, and the presence of progesterone receptors in certain muscle and fat tissue may hint at a role in sexually dimorphic proportions of those. During pregnancy, progesterone is said to decrease uterine irritability. During pregnancy, progesterone helps to suppress immune responses of the mother to fetal antigens, thus preventing rejection of the fetus. Progesterone raises epidermal growth factor-1 (EGF-1) levels, a factor often used to induce proliferation of stem cells, and used to sustain stem cell cultures. Progesterone increases core temperature (thermogenic function) during ovulation. Progesterone reduces spasm and relaxes smooth muscle. Bronchi are widened and mucus regulated. (PRs are widely present in submucosal tissue.) Progesterone acts as an anti-inflammatory agent and regulates the immune response. Progesterone reduces gallbladder activity. Progesterone normalizes blood clotting and vascular tone, zinc and copper levels, cell oxygen levels, and use of fat stores for energy. Progesterone may affect gum health, increasing risk of gingivitis (gum inflammation). Progesterone appears to prevent endometrial cancer (involving the uterine lining) by regulating the effects of estrogen. Progesterone plays an important role in the signaling of insulin release and pancreatic function, and it may affect the susceptibility to diabetes or gestational diabetes.
Sources: en.wikipedia.org
The critical structural element of all glycoproteins is having oligosaccharides bonded covalently to a protein. There are 10 common monosaccharides in mammalian glycans including: glucose (Glc), fucose (Fuc), xylose (Xyl), mannose (Man), galactose (Gal), N-acetylglucosamine (GlcNAc), glucuronic acid (GlcA), iduronic acid (IdoA), N-acetylgalactosamine (GalNAc), sialic acid, and 5-N-acetylneuraminic acid (Neu5Ac). These glycans link themselves to specific areas of the protein amino acid chain. The two most common linkages in glycoproteins are N-linked and O-linked glycoproteins. An N-linked glycoprotein has glycan bonds to the nitrogen containing an asparagine amino acid within the protein sequence. An O-linked glycoprotein has the sugar is bonded to an oxygen atom of a serine or threonine amino acid in the protein. Glycoprotein size and composition can vary largely, with carbohydrate composition ranges from 1% to 70% of the total mass of the glycoprotein. Within the cell, they appear in the blood, the extracellular matrix, or on the outer surface of the plasma membrane, and make up a large portion of the proteins secreted by eukaryotic cells. They are very broad in their applications and can function as a variety of chemicals from antibodies to hormones.
=== Humanitarian work === Collins is a supporter of animal rights. She has appeared in numerous campaigns for the animal rights organisation PETA. In 2013, she posed naked for the "I'd Rather Go Naked Than Wear Fur" campaign. In 2020, Collins was photographed in a bathtub to highlight the fact that marine animals are separated from their families and confined to concrete tanks. In 2021, she posed with a skinned fox as she backed the campaign to end the fur trade in the United Kingdom. Addressing then prime minister Boris Johnson, Collins said "Take it from an icon, Boris – no one needs fur in their wardrobe. Do the right thing – ban fur imports and sales. Let's wear our skin and let the animals keep theirs." Speaking on her podcast, Collins expressed her interest in becoming a humanitarian and said she wishes to promote conservation and animal welfare to the next generation. In November 2022, Collins opened a newly refurbished Cats Protection adoption centre in Chelmsford, during which she was given a tour and the opportunity to name one of the cats, which she named after Mr. Mistoffelees from Cats. Following the re-opening, Collins said she was "putting out a plea to help these amazing people give cats a home". In March 2023, Collins assisted with the launch of the Be A Cat Cafe in Soho, a pop-up experience from cat food brand Felix. Attending the event, Collins said "I'm here for cattitude and think that if people tried being more like a cat, they'd be a lot more chilled out and relaxed".
=== Host immune response === Fibroblasts from different anatomical sites in the body express many genes that code for immune mediators and proteins. These mediators of immune response enable the cellular communication with hematopoietic immune cells. The immune activity of non-hematopoietic cells, such as fibroblasts, is referred to as "structural immunity". In order to facilitate a fast response to immunological challenges, fibroblasts encode crucial aspects of the structural cell immune response in the epigenome.
In "yellowsolve" methods, a red dye in dilute acetic acid is first applied, then the section is very thoroughly dehydrated to ensure that no moisture remains. The red dye is then displaced by a yellow dye in a solvent, such as cellosolve (2-ethoxy-ethanol). The name yellowsolve is a blend of the terms yellow and cellosolve. Lendrum's phloxine-tartrazine for cell inclusions is one example of a yellowsolve stain.
248Cm(13C,xn)261−xNo (x=3?,4,5) This reaction was first studied in 1967 at the LBNL. The new isotopes 258No,257No and 256No were detected in the 3-5n channels. The reaction was repeated in 1970 to provide further decay data for 257No.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.